Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage ...

That is the thesis of Harness CEO Jyoti Bansal, whose company has been working to bring more trustworthy autonomy to these ...

MindWalk Holdings Corp. reported record sales, improved margins, and a strengthened balance sheet post-divestiture. Learn ...

Many people find that using Python for their LeetCode solutions really helps speed things up. It’s not just about writing ...

Recursion Pharmaceuticals' stock rises on heavy trading volume, with investors eyeing its AI-designed cancer drug REC-3565 ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In recent days, Recursion Pharmaceuticals attracted heightened attention as traders responded to the stock’s very large short interest, alongside the announcement of a $12.5 million milestone payment ...

Recursion Pharmaceuticals RXRX stock surged 16% in early October 2025 on renewed AI interest despite posting $171.9 million ...